Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hannah Boaz

Nurse Practitioner, Psychiatric/Mental Health Harrison, AR Nurse Practitioner

NPI 1881384949 CMS profile 11480467

303 W Newman Ave, Harrison, AR 72601

Open in the dashboard

General payments

$4,587

262 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Boaz of Harrison, AR is reported in the CMS Open Payments database as having received $4,587 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,835 116
2024 General $1,918 100
2023 General $824 45
2022 General $9 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Boaz
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Hannah Boaz were reported at $1,835. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Hannah Boaz Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $9 $195 $66–$559 $149
2023 $824 $233 $82–$673 $160
2024 $1,918 $236 $84–$688 $164
2025 $1,835 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. ITI, Inc. $784 70 payments
  2. Neurocrine Biosciences, Inc. $749 34 payments
  3. Otsuka America Pharmaceutical, Inc. $513 28 payments
  4. AbbVie, Inc. $474 31 payments
  5. Alkermes, Inc. $325 20 payments
  6. Axsome Therapeutics, Inc. $316 12 payments
  7. Vanda Pharmaceuticals Inc. $246 11 payments
  8. Lundbeck LLC $237 17 payments
  9. E.R. Squibb & Sons, L.L.C. $236 6 payments
  10. Janssen Pharmaceuticals, Inc $169 3 payments
  11. Other $539 30 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,587 262 payments
Products named General payments · program years 2022–2025
  1. INGREZZA $744 33 payments
  2. CAPLYTA Psychiatry $470 41 payments
  3. LYBALVI $325 20 payments
  4. ARISTADA Cns $325 20 payments
  5. ARISTADA Cns $325 20 payments
  6. ARISTADA Cns $325 20 payments
  7. ARISTADA Cns $325 20 payments
  8. Auvelity $316 12 payments
  9. CAPLYTA Psychiatry $313 29 payments
  10. REXULTI $312 17 payments
  11. Other $2,104 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,781

Median for Nurse Practitioner: 389

Drug cost

$569,113

Median for Nurse Practitioner: $21,885

Branded share of claims

24.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 39 $323,303
Caplyta Lumateperone Tosylate Brand 38 $66,563
Abilify Maintena Aripiprazole Brand 20 $56,143
Rexulti Brexpiprazole Brand 25 $43,989
Vraylar Cariprazine Hcl Brand 18 $37,378
Aripiprazole Generic 122 $9,052
Quetiapine Fumarate Er Quetiapine Fumarate Brand 34 $5,708
Belsomra Suvorexant Brand 12 $5,229
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 14 $2,379
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 72 $1,949

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$15,311

Medicare's payments for the services billed

Medicare patients

41

Average age 61

Services billed

293

19 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 73%
High blood pressure 63%
Arthritis 34%
Diabetes 32%
Ischemic heart disease 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $294
$294 39 —
CAPLYTA
  • ITI, Inc. $290
$290 38 —
Auvelity
  • Axsome Therapeutics, Inc. $261
$261 — —
VRAYLAR
  • AbbVie, Inc. $215
$215 18 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $149
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record